Influenza Vaccine – V201_03

A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a High- Dose MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc HD) in Comparison with a Nonadjuvanted Quadrivalent Recombinant Influenza Vaccine (QIVr) and an MF59-Adjuvanted Quadrivalent Subunit Egg-derived Influenza Vaccine (aQIV), in Adults Aged 50 Years and Above

Register Today!

Trial Information

Start DateSeptember 2023
End DateTBD
Trial Duration6 months
Number of Visits6
Lead CRCAndrea Carruthers
StatusON HOLD until September 2023

For additional information
on this trial contact: